June 01, 2024

Antibody-Drug Conjugate Plus Checkpoint Inhibitor for PD-L1–Positive, HR-Positive/HER2-Negative Breast Cancer

The phase II SACI-IO HR+ trial—results of which were presented at the 2024 ASCO Annual Meeting—was designed to evaluate whether sacituzumab govitecan-hziy and pembrolizumab work synergistically in pat...

July 25, 2024

Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting

The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentu...

July 16, 2024

A Role for Avelumab in Triple-Negative Breast Cancer?

In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly imp...

June 03, 2024

USP1 Inhibitor in Metastatic Solid Tumors

The first-in-class ubiquitin-specific peptidase 1 (USP1) inhibitor RO7623066 showed a positive safety profile as a single agent and signs of early antitumor activity in patients with advanced solid tu...

June 03, 2024

Study Including Only Black Patients With Breast Cancer Compares Rates of Taxane-Induced Peripheral Neuropathy

New findings suggest that docetaxel may be considered the preferred treatment over paclitaxel for Black patients with early-stage breast cancer. While the EAZ171 trial focused specifically on Black pe...

June 05, 2024

New Study Highlights Benefits of Stepped Palliative Care in Advanced Lung Cancer

Researchers have uncovered the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings presented at the 2024 ASCO Annual Meet...

July 10, 2024

Novel Antibody-Drug Conjugate Extends Survival vs Chemotherapy in Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, ac...

June 02, 2024

Telehealth Shown to Be Effective for Palliative Care Delivery in Patients With Advanced Lung Cancer

New research presented at the 2024 ASCO Annual Meeting reinforces the telehealth delivery of palliative care as an effective alternative to in-person visits for patients with advanced lung cancer, pro...

June 01, 2024

American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration

The American Cancer Society and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership will create one of the l...

October 24, 2024

Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More, Part 2

In the October 10, 2024, issue of The ASCO Post, we shared some unique insights from several recipients of the international development and education award (IDEA). As oncologists and cancer researche...

July 25, 2024

A Role for Avelumab in Triple-Negative Breast Cancer?

In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly imp...

June 24, 2024

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma

The final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free survival—as well as a 20% lower risk of death—with adj...

June 07, 2024

Addition of Chemoradiation to Adjuvant Systemic Therapy: Differences in Node-Negative vs Node-Positive Pancreatic Cancer

Does adding chemoradiation to adjuvant systemic therapy improve survival outcomes in patients with resected periampullary pancreatic adenocarcinoma? A study presented at the 2024 ASCO Annual Meeting i...

July 10, 2024

Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer

Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–muta...

June 25, 2024

Durvalumab Consolidation Therapy Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer compared with standard-of-care chemoradiotherap...

June 03, 2024

Telehealth May Reduce Greenhouse Gas Emissions Associated With Cancer Care

Telemedicine visits for cancer care are not only more convenient and possibly easier to schedule than in-person appointments—they may also be better for the planet. These findings were presented at th...

June 04, 2024

Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma

A novel “armored” type of chimeric antigen receptor (CAR) T-cell therapy may prove to be effective in patients with non-Hodgkin lymphoma who do not respond to standard CAR T-cell therapy, according to...

May 23, 2024

HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females

A retrospective cohort study found evidence that the human papillomavirus (HPV) vaccine was efficacious in the prevention of several types of malignancies and premalignant dysplasia caused by HPV.

June 01, 2024

CAR T-Cell Therapy in Patients With Central Nervous System Lymphoma

A CAR T-cell therapy approved for patients with large B-cell lymphoma has produced positive results in a pilot study involving patients with relapsed, treatment-resistant CNS lymphoma. Results were pr...

June 01, 2024

Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates

The novel anti-CD19 autologous CAR T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell ALL without a subsequent stem cell transplan...

July 17, 2024

Long-Term Survival Possible After Liver Transplant for Colorectal Liver Metastases

In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicente...

June 25, 2024

Retroperitoneal Lymphadenectomy: Can It Be Safely Omitted for Some Patients With Advanced Ovarian Cancer?

Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or ...

June 20, 2024

Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?

A novel treatment combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in patients with metastatic colorectal cancer who previously underwent standar...

June 18, 2024

Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC

Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemorad...

June 07, 2024

Study Identifies Subset of Patients With Lung Adenocarcinoma Who Have HER2 Alterations

Researchers have found that a proportion of patients with NSCLC and KRAS, EGFR, or ALK gene mutations may also have HER2 alterations, according to findings presented at the 2024 ASCO Annual Meeting.